NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis

NINDS 神经科学卓越网络：加州大学戴维斯分校的临床研究中心

• 批准号: 10213857
• 负责人: Craig M. McDonald
• 金额: $ 28.63万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10213857
• 关键词: Address; Adult; Affect; Biological Markers; California; Capital; Characteristics; Childhood; Cities; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Communities; Community Outreach; Country; Data; Data Coordinating Center; Development; Disease; Doctor of Philosophy; Environment; Foundations; Functional disorder; Future; Goals; Health; Health system; Industry; Informatics; Infrastructure; Institutional Review Boards; Link; Metadata; Mission; Multi-Institutional Clinical Trial; National Institute of Neurological Disorders and Stroke; Natural History; Neurosciences; Neurosciences Research; Outcome; Patient Recruitments; Patients; Personal Satisfaction; Phase II Clinical Trials; Population; Positioning Attribute; Preparation; Protocols documentation; Public Health; Quality of life; Registries; Research; Research Infrastructure; Research Personnel; Research Training; Resource Informatics; Resources; Site; Specialist; Standardization; System; Testing; Translational Research; United States National Institutes of Health; Universities; Vision; Work; burden of illness; career; catalyst; clinical outcome measures; clinical research site; community engagement; design; drug development; drug discovery; experience; improved; improved functioning; innovation; nervous system disorder; new therapeutic target; novel therapeutics; outreach; phase 2 study; public-private partnership; response; skills; sound; success; supportive environment; telehealth; therapeutic development; translational pipeline; translational research program

NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis (PI: Craig M. McDonald, MD; Sub‐PI: Michael Rogawski, MD, PhD) This proposal contributes to the NINDS Network for Excellence in Neuroscience (NeuroNEXT) by renewing a clinical research site at the University of California Davis Health System located in Sacramento, CA, the capital of the most populous state in the country and one of the most diverse and integrated cities in the U.S. The UC Davis NeuroNEXT clinical research site will continue to contribute to the mission of NINDS by reducing the burden of neurologic diseases, and contribute an infrastructure which expands the NINDS capability to test promising new therapies, increase the efficiency of clinical trials, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. Our experience as an existing NeuroNEXT site, neuroscience research excellence at UC Davis ‐ the most comprehensive campus in the University of California system, a robust translational research infrastructure housed in a nationally recognized, experienced, and competitively renewed NIH CTSA (the UC Davis CTSC), neuroscience research excellence, an innovative collaborative drug development pipeline from the University of California UC BRAID Drug Discovery Consortium, a national center of excellence in telehealth strategically positioned to promote community outreach, an innovative informatics such as the Tethered Metadata Registry for case identification, and access to diverse patients with neurological disorders managed in a highly ranked regional health system with active clinical affiliations, all work synergistically to position UC Davis to continue to be an outstanding Clinical Research Site for the NeuroNEXT network. UC Davis NeuroNEXT aims to: 1) Leverage existing resources and expertise to serve as a NeuroNEXT hub for implementing multicenter neuroscience clinical trials, increasing the efficiency and quality of trials conducted at the UC Davis site; 2) Collaborate with the University of California UC BRAID Drug Discovery Consortium to serve as a core resource for NeuroNEXT and function as a catalyst for innovative therapeutic development across the translational spectrum; 3) Provide local and regional community outreach to improve patient recruitment and retention and fully integrate community partners into the translational research enterprise; 4) Efficiently utilize, diversify, and leverage innovative telehealth and informatics resources for clinical trials; and 5) Provide collaborative and innovative clinical research training and a supportive environment for diverse early‐career investigators to develop additional research skills and become independent clinical investigators. Our accomplishments to date – locally, regionally, and nationally – provide an outstanding foundation for future success.

NINDS神经科学卓越网络：加州大学戴维斯分校临床研究中心（PI：克雷格M。McDonald，MD;助理PI：Michael Rogawski，MD，PhD）该提案有助于NINDS神经科学卓越网络（NeuroNEXT）通过更新位于加利福尼亚州萨克拉门托的加州戴维斯卫生系统大学的临床研究站点，加州大学戴维斯分校NeuroNEXT临床研究中心将继续为使命做出贡献通过减少神经系统疾病的负担，为NINDS提供基础设施，扩大NINDS测试有前途的新疗法的能力，提高临床试验的效率，并在新的机会出现时迅速做出反应，以测试有前途的治疗神经系统疾病的人。我们作为现有NeuroNEXT网站的经验，加州大学戴维斯分校的神经科学研究卓越-加州系统最全面的校园，一个强大的转化研究基础设施，位于全国公认的，经验丰富的，具有竞争力的更新NIH CTSA（加州大学戴维斯分校CTSC），神经科学研究卓越，创新的合作药物开发管道从加州大学伯克利分校药物发现联盟，卓越的远程医疗战略定位，以促进社区外展的国家中心，创新的信息学，如用于病例识别的系留元数据登记处，以及在具有活跃临床联系的高排名区域卫生系统中管理的神经系统疾病患者的访问，所有这些都协同工作，使加州大学戴维斯分校继续成为NeuroNEXT网络的杰出临床研究中心。UC Davis NeuroNEXT旨在：1）利用现有的资源和专业知识，作为NeuroNEXT中心，实施多中心神经科学临床试验，提高在加州大学戴维斯分校进行的试验的效率和质量; 2）与加州大学BRAID药物发现联盟合作，作为NeuroNEXT的核心资源，并作为跨翻译谱创新治疗开发的催化剂; 3）提供当地和区域社区外展服务，以改善患者招募和保留，并将社区合作伙伴充分融入转化研究企业; 4）有效利用、多样化和利用创新的远程医疗和信息学资源进行临床试验;（五）为不同的早期职业研究者提供协作和创新的临床研究培训和支持性环境，以发展更多的研究技能，成为独立的临床研究者。我们迄今为止在地方、区域和全国取得的成就为未来的成功奠定了坚实的基础。